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Previewsestablish the signaling pathways acti-
vated by T. gondii ROP kinases in tissue
macrophages as a complement to in vitro
studies. Third, the clear lines of CAM and
AAM macrophage activation are unlikely
to occur in humans or even in rodent
tissue macrophages: human macro-
phages and DCs do not readily activate
either Arg1 or iNOS, and therefore the
interplay between T. gondii and human
cells seems an important direction for
the field.
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Integration of reverse transcribed HIV-1 DNA into the host genome, catalyzed by HIV-1 integrase, represents
an obligate step in establishing productive viral infection. Allouch et al. (2011) identify KAP1 (TRIM28) as an
interaction partner of acetylated integrase. KAP1, in complex with HDAC1, represses HIV-1 integration
through specific deacetylation of HIV-1 integrase.Like all retroviruses, HIV must reverse
transcribe its RNA genome into DNA and
insert this DNA into the host cell genome.
This process, known as integration, is an
essential early step in establishing a stable
and productive infection. The integration
process is catalyzed by HIV-1 integrase
(IN) and takes place within the preintegra-
tion complex (PIC), a large macromolec-
ular structure, which contains approxi-
mately 10 kb of viral DNA, along with viral
andcellular proteins.While in vitro integra-
tion can be solely driven by IN, cellular
cofactors clearly play an essential role for
in vivo HIV-1 integration. Since integration
is a vital step in HIV-1 infection, develop-
ment of antiviral drugs against IN activity
and identification of candidate cofactors
of retroviral integration remain a key focus
of investigations.
Considerable effort has been made to
identify viral and cellular components
involved in HIV-1 integration by variousassays including in vitro reconstitution of
enzymatic activity of salt-stripped PICs,
yeast two-hybrid screens, andcoimmuno-
precipitation. These in vitro assays have
identified an arsenal of candidate cofac-
tors and have provided insights into the
cellular pathways and complexes previ-
ously unsuspected of being involved in
retroviral integration. One of the better
studied cellular cofactors for integration
is LEDGF/p75, a cellular stress-response
factor and transcriptional coactivator (Ge
et al., 1998). An unexpected link between
LEDGF/p75 and HIV was initially identified
following a coimmunoprecipitation study
of the HIV-1 IN complexes present in
nuclei of human cells that stably overex-
press the HIV-1 IN from a synthetic gene
(Cherepanov et al., 2003). An in vivo role
for LEDGF/p75 in HIV-1 replication has
been validated by several groups. For
other putative cofactors of HIV-1 integra-
tion, it remains a challenge to clearlyestablish functional relevance of potential
cellular factors of viral integration in vivo.
In this issue, the Cereseto laboratory
(Allouch et al., 2011) identifies a cellular
factor that posttranslationally modulates
HIV-1 IN activity.
A prior study from the Cereseto labora-
tory (Cereseto et al., 2005) identified a
function for p300, a cellular acetyltrans-
ferase known to acetylate histones and
regulate chromatin, in mediating acetyla-
tion of HIV-1 IN. Acetylation by p300
was shown to increase both IN affinity
for DNA and strand transfer activity, thus
suggesting relevance for IN posttransla-
tion modification by acetylation. Three
lysine residues, located at positions 264,
266, and 273 in the C-terminal domain
of IN, were identified as the acetylation
target sites (Cereseto et al., 2005). A mu-
tant virus in which arginine substitutions
were introduced at p300-targeted IN
lysines was shown to be less efficient ate 9, June 16, 2011 ª2011 Elsevier Inc. 447
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p300 is known to impact the ability of a
variety of DNA-binding proteins to interact
specifically with their respective target
DNAs, it seemed reasonable that HIV inte-
gration could be modulated by an acety-
lation mechanism. To gain a more com-
plete understanding of this process,
cellular factors involved in the acetylation
of HIV IN need to be identified.
In the current study, Cereseto and
colleagues developed a clever tethered
catalysis yeast two-hybrid screen to iden-
tify cellular factors that preferentially
interactwithacetylatedHIV-1 IN.Toassure
that the IN used in a yeast two-hybrid is
properly acetylated, they utilized a fusion
protein of IN and the histone acetyltrans-
ferase (HAT) catalytic domain of p300.
Therefore, the HIV-1 IN ‘‘bait’’ presented
in the screen is constitutively acetylated.
The successful use of this modified two-
hybrid system provides proof of concept
for the application of this method for the
systematic analysis of virus-host interac-
tions that are dependent on specific post-
translational modifications.
One of the identified binding factors
was KAP1, which showed a higher affinity
to IN following its acetylation. Cereseto
and colleagues confirmed this interaction
by pull-down assays and in vivo coimmu-
noprecipitation in 293T cells. To validate
the role of KAP1 during the HIV-1 life
cycle, infections were performed in HeLa
and 293T cells transiently or stably
silenced for KAP1. Interestingly, KAP1
downregulation enhanced viral infectivity
compared to control cells while overex-
pression of KAP1 showed a reduction of
infectivity. This indicates that KAP1 is
a negative regulator of HIV-1 integration.
Analysis of reverse transcripts and nu-
clear localizations using real-time quanti-
tative PCR revealed that the influence of
KAP1 is specific to integration of HIV.
The levels of late reverse transcripts did
not change when KAP1 expression levels
were altered. In contrast, analysis of dif-
ferent forms of viral cDNA showed a spe-
cific enhancement of 2-LTR circles, which
are a marker for viral genome nuclear
localization. The decrease in integration
products inversely correlates with the
increase in 2-LTR circles indicating that448 Cell Host & Microbe 9, June 16, 2011 ª2nuclear import is not influenced by KAP1.
This negative regulation of HIV-1 integra-
tion by KAP1 is modulated by HDAC1, a
known KAP1 interaction partner. The for-
mation of a KAP1-HDAC1-IN complex
was demonstrated by coimmunoprecipi-
tation of epitope-tagged HDAC1 and IN.
A functional role of HDAC1 in the modula-
tion of HIV integration was supported in
gene-knockdown experiments. HDAC1
knockdown increased HIV integration
and infection. Likewise, the inhibition of
HDAC1 with the small molecule trichosta-
tin A (TSA) or MS-275 led to an increase in
integration. Collectively, these findings
demonstrate that KAP1 interaction with
acetylated IN induces KAP1-HDAC1
complex formation, leading to IN deacety-
lation and reduced integration efficiency.
This is not the first connection identified
between KAP1, also known as TRIM28,
and retroviral biology. TRIM28 was previ-
ously identified as a transcriptional core-
pressor of M-MLV and binds to the Kru¨p-
pel-associated box (KRAB) repression
domain found in many transcription fac-
tors (Wolf and Goff, 2007). KAP1/TRIM28
is a member of the tripartite motif (TRIM)
family of proteins involved in antiviral re-
sponses. Interestingly, this study showed
no effect on M-MLV cDNA integration
indicating a virus-specific aspect of KAP1
activity on HIV integration. In M-MLV,
KAP1-mediated transcriptional repres-
sion occurs when KAP1 binds to the
proviral primer binding site (PBS) contain-
ing tRNAPro complementary sequences.
The HIV-1 PBS lacks tRNAPro comple-
mentary sequences and thus may explain
a lack of KAP1-mediated transcriptional
repression in HIV-1. However, KRAB box
transcription factors engineered to target
the HIV-1 PBS mediated transcriptional
silencing of HIV-1 provirus (Eberhardy
et al., 2006). Thus, KAP1 might have an
as yet undetermined role in HIV-1 tran-
scription. KAP1 contains no intrinsic tran-
scriptional activity and therefore interacts
with cofactors that specifically serve its
function during viral transcription. The
relation of these potential multiple activi-
ties of KAP1 in HIV replication remains to
be determined.
The studies presented here underscore
the importance of posttranslational modi-011 Elsevier Inc.fication of IN for HIV-1 replication. A
complex of KAP1 and HDAC1 can deace-
tylate HIV-1 IN, downregulating the effi-
ciency of HIV-1 integration. However,
many questions regarding how this inter-
action can alter HIV replication during
infection need to be answered. Is the
acetylation state of HIV-1 IN cell-type
specific, virus-strain specific, or influ-
enced by different states of cellular acti-
vation? Are these changes mediated by
the activity of KAP1 and HDAC1, or are
there other pathways that can modulate
HIV IN acetylation? Further studies will
clarify the molecular mechanisms by
which HIV-1 IN acetylation controls IN
activities during the early steps of viral
replication. Cereseto and coworkers also
identified 12 other cellular factors in their
modified yeast two hybrid. It will be inter-
esting not only to determine how these
other factors influence IN activity but how
posttranslational acetylation influences
HIV replication will also be of interest for
future studies.
Currently, there are numerous anti-HIV
therapies that specifically target IN. By
elucidating a pathway through which IN
is regulated, the authors potentially have
uncovered a new target for next-genera-
tion drugs to treat infection with HIV.ACKNOWLEDGMENTS
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